338 related articles for article (PubMed ID: 12089223)
21. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
[TBL] [Abstract][Full Text] [Related]
22. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
Allen JD; Van Dort SC; Buitelaar M; van Tellingen O; Schinkel AH
Cancer Res; 2003 Mar; 63(6):1339-44. PubMed ID: 12649196
[TBL] [Abstract][Full Text] [Related]
23. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
24. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
[TBL] [Abstract][Full Text] [Related]
25. Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers.
Li N; Song Y; Du P; Shen Y; Yang J; Gui L; Wang S; Wang J; Sun Y; Han X; Shi Y
Biomed Pharmacother; 2013 Oct; 67(8):801-6. PubMed ID: 24074809
[TBL] [Abstract][Full Text] [Related]
26. In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib.
Kawamura K; Yamasaki T; Yui J; Hatori A; Konno F; Kumata K; Irie T; Fukumura T; Suzuki K; Kanno I; Zhang MR
Nucl Med Biol; 2009 Apr; 36(3):239-46. PubMed ID: 19324269
[TBL] [Abstract][Full Text] [Related]
27. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.
Breedveld P; Beijnen JH; Schellens JH
Trends Pharmacol Sci; 2006 Jan; 27(1):17-24. PubMed ID: 16337012
[TBL] [Abstract][Full Text] [Related]
28. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
29. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
[TBL] [Abstract][Full Text] [Related]
30. N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk.
Wang L; Leggas M; Goswami M; Empey PE; McNamara PJ
Drug Metab Dispos; 2008 Dec; 36(12):2591-6. PubMed ID: 18799806
[TBL] [Abstract][Full Text] [Related]
31. PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein.
Yamasaki T; Kawamura K; Hatori A; Yui J; Yanamoto K; Yoshida Y; Ogawa M; Nengaki N; Wakisaka H; Fukumura T; Zhang MR
Nucl Med Commun; 2010 Nov; 31(11):985-93. PubMed ID: 20859232
[TBL] [Abstract][Full Text] [Related]
32. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel.
Kwak JO; Lee SH; Lee GS; Kim MS; Ahn YG; Lee JH; Kim SW; Kim KH; Lee MG
Eur J Pharmacol; 2010 Feb; 627(1-3):92-8. PubMed ID: 19903471
[TBL] [Abstract][Full Text] [Related]
33. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.
Oostendorp RL; Buckle T; Beijnen JH; van Tellingen O; Schellens JH
Invest New Drugs; 2009 Feb; 27(1):31-40. PubMed ID: 18449471
[TBL] [Abstract][Full Text] [Related]
34. In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats.
Matsuda Y; Konno Y; Hashimoto T; Nagai M; Taguchi T; Satsukawa M; Yamashita S
Drug Metab Dispos; 2013 Aug; 41(8):1514-21. PubMed ID: 23686319
[TBL] [Abstract][Full Text] [Related]
35. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Allen JD; van Loevezijn A; Lakhai JM; van der Valk M; van Tellingen O; Reid G; Schellens JH; Koomen GJ; Schinkel AH
Mol Cancer Ther; 2002 Apr; 1(6):417-25. PubMed ID: 12477054
[TBL] [Abstract][Full Text] [Related]
36. Local Drug-Drug Interaction of Donepezil with Cilostazol at Breast Cancer Resistance Protein (ABCG2) Increases Drug Accumulation in Heart.
Takeuchi R; Shinozaki K; Nakanishi T; Tamai I
Drug Metab Dispos; 2016 Jan; 44(1):68-74. PubMed ID: 26467765
[TBL] [Abstract][Full Text] [Related]
37. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat.
Letrent SP; Pollack GM; Brouwer KR; Brouwer KL
Pharm Res; 1998 Apr; 15(4):599-605. PubMed ID: 9587957
[TBL] [Abstract][Full Text] [Related]
38. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
Perego P; De Cesare M; De Isabella P; Carenini N; Beggiolin G; Pezzoni G; Palumbo M; Tartaglia L; Pratesi G; Pisano C; Carminati P; Scheffer GL; Zunino F
Cancer Res; 2001 Aug; 61(16):6034-7. PubMed ID: 11507048
[TBL] [Abstract][Full Text] [Related]
39. Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513.
Salphati L; Plise EG; Li G
Eur J Pharm Sci; 2009 Jun; 37(3-4):463-8. PubMed ID: 19491037
[TBL] [Abstract][Full Text] [Related]
40. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
Poller B; Wagenaar E; Tang SC; Schinkel AH
Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]